Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control
It could broaden access to metabolic health tools, giving those who cant afford, tolerate, or qualify for prescription GLP-1s another option
Practical Considerations for Prescribers When planning treatment strategies in 2026, its important to address the side effects of metformin, its affordability, and how it compares to newer medications in patient-specific contexts
The medication's effects on insulin sensitivity and modest weight loss often lead to resumption of ovulation and regular cycles within 3-6 months
Other trials are examining retatrutides effects in individuals with associated health conditions such as type 2 diabetes or heart disease, given their prevalence in those with obesity
These symptoms typically resolve as the body adapts to lower insulin levels and the associated fluid shifts